BRPI0815564B8 - anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met - Google Patents
anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-metInfo
- Publication number
- BRPI0815564B8 BRPI0815564B8 BRPI0815564A BRPI0815564A BRPI0815564B8 BR PI0815564 B8 BRPI0815564 B8 BR PI0815564B8 BR PI0815564 A BRPI0815564 A BR PI0815564A BR PI0815564 A BRPI0815564 A BR PI0815564A BR PI0815564 B8 BRPI0815564 B8 BR PI0815564B8
- Authority
- BR
- Brazil
- Prior art keywords
- met
- antibody
- antibodies
- inhibit
- underexpression
- Prior art date
Links
- 238000006471 dimerization reaction Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001529936 Murinae Species 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004408 hybridoma Anatomy 0.000 title 1
- 230000016784 immunoglobulin production Effects 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000002018 overexpression Effects 0.000 title 1
- 230000009452 underexpressoin Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92978907P | 2007-07-12 | 2007-07-12 | |
| EP07301231A EP2014681A1 (en) | 2007-07-12 | 2007-07-12 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US2063908P | 2008-01-11 | 2008-01-11 | |
| PCT/EP2008/059026 WO2009007427A2 (en) | 2007-07-12 | 2008-07-10 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0815564A2 BRPI0815564A2 (pt) | 2015-02-18 |
| BRPI0815564B1 BRPI0815564B1 (pt) | 2020-01-21 |
| BRPI0815564B8 true BRPI0815564B8 (pt) | 2021-05-25 |
Family
ID=38871713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815564A BRPI0815564B8 (pt) | 2007-07-12 | 2008-07-10 | anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met |
Country Status (35)
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2143441A1 (en) | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US20140112911A9 (en) * | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| CN102361883A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
| PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR101671378B1 (ko) | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| KR101748707B1 (ko) | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
| JP6055312B2 (ja) * | 2010-03-10 | 2017-01-11 | ゲンマブ エー／エス | Ｃ−ｍｅｔに対するモノクローナル抗体 |
| JP2013534515A (ja) * | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体 |
| EP2402370A1 (en) * | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| JP2013537966A (ja) | 2010-08-31 | 2013-10-07 | ジェネンテック， インコーポレイテッド | バイオマーカー及び治療の方法 |
| SG188324A1 (en) | 2010-09-03 | 2013-04-30 | Academia Sinica | Anti-c-met antibody and methods of use thereof |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US8637027B2 (en) | 2010-11-03 | 2014-01-28 | Argen-X B.V. | Anti c-Met antibodies |
| EP2643351A1 (en) | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| KR101444837B1 (ko) * | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| CN106046168A (zh) * | 2011-06-23 | 2016-10-26 | 埃博灵克斯股份有限公司 | 结合血清白蛋白的蛋白 |
| SG194982A1 (en) | 2011-06-23 | 2013-12-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2013003680A1 (en) * | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| HK1199883A1 (en) | 2011-08-26 | 2015-07-24 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| KR20140064971A (ko) | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| EP2758430A4 (en) | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
| JP6219287B2 (ja) * | 2011-09-30 | 2017-10-25 | アブリンクス エン．ヴェー． | ｃ−Ｍｅｔに関連する生物学的物質 |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| KR101865223B1 (ko) * | 2011-10-05 | 2018-06-08 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| WO2013064700A2 (en) | 2011-11-03 | 2013-05-10 | Argen-X B.V. | Chimeric polypeptides and methods of use |
| WO2013078170A1 (en) | 2011-11-21 | 2013-05-30 | Genentech, Inc. | Purification of anti-c-met antibodies |
| US20150147274A1 (en) | 2011-12-02 | 2015-05-28 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
| US8900582B2 (en) | 2011-12-22 | 2014-12-02 | Samsung Electronics Co., Ltd. | Deimmunized anti c-Met humanized antibodies and uses thereof |
| WO2013130565A1 (en) * | 2012-02-29 | 2013-09-06 | The Brigham And Women's Hosptial, Inc. | Neutralizing antibody for epstein barr virus associated disease |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP6429771B2 (ja) | 2012-06-21 | 2018-11-28 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ｃ−Ｍｅｔに結合する抗原結合タンパク質 |
| KR101938698B1 (ko) | 2012-07-23 | 2019-01-16 | 삼성전자주식회사 | Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도 |
| KR101938699B1 (ko) | 2012-07-23 | 2019-01-16 | 삼성전자주식회사 | Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도 |
| AU2013302441B2 (en) * | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Ｓｃｉｖａｘ株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
| EP2839860B1 (en) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| WO2014074907A1 (en) * | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| KR101911048B1 (ko) | 2013-01-29 | 2018-10-24 | 삼성전자주식회사 | ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물 |
| HK1211235A1 (en) | 2013-02-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| KR102139607B1 (ko) * | 2013-04-01 | 2020-07-30 | 삼성전자주식회사 | 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| WO2015031614A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015031626A1 (en) | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| US9717715B2 (en) | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
| CA2943329A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| CA2944717A1 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| AU2015316522B2 (en) | 2014-09-16 | 2021-01-21 | Symphogen A/S | Anti-met antibodies and compositions |
| EP3200825A4 (en) | 2014-10-03 | 2018-03-21 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| WO2016053610A1 (en) * | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| US11035860B2 (en) * | 2014-11-20 | 2021-06-15 | Stichting Katholieke Universiteit | Auto-active and intracellular mutant of MET |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| EP3233910B1 (en) | 2014-12-19 | 2019-12-11 | Ablynx N.V. | Cysteine linked nanobody dimers |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| CN107613974B (zh) * | 2015-03-16 | 2021-01-15 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| US10273305B2 (en) | 2015-04-02 | 2019-04-30 | Ablynx N.V. | Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity |
| TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| US20190194345A1 (en) * | 2015-10-05 | 2019-06-27 | University Of Virginia Patent Foundation | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer |
| JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
| WO2017173091A1 (en) * | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
| ES2864150T3 (es) | 2016-05-17 | 2021-10-13 | Abbvie Biotherapeutics Inc | Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso |
| BR112019000166A2 (pt) * | 2016-07-06 | 2019-10-01 | Celgene Corp | anticorpos com baixa imunogenicidade e usos dos mesmos |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RECOMBINANT ANTIBODIES BINDING TO CD123 |
| WO2019117691A1 (ko) * | 2017-12-15 | 2019-06-20 | 경북대학교 산학협력단 | CD44v6에 결합하는 펩타이드 및 이의 용도 |
| KR102194025B1 (ko) | 2017-12-15 | 2020-12-22 | 경북대학교 산학협력단 | CD44v6에 결합하는 펩타이드 및 이의 용도 |
| EP3772927B1 (en) * | 2018-03-24 | 2025-01-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| KR20210016562A (ko) | 2018-05-23 | 2021-02-16 | 에이디씨 테라퓨틱스 에스에이 | 분자 애쥬번트 |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN109541221B (zh) * | 2018-10-24 | 2022-03-22 | 益善生物技术股份有限公司 | 一种c-Met特异性抗体、组合物及试剂盒 |
| CN115605491A (zh) | 2019-04-05 | 2023-01-13 | 刘扶东（Us） | 抗唾液酸酶的糖类、其制造方法及用途 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| CA3182526A1 (en) | 2020-05-08 | 2021-11-11 | Academia Sinica | Chimeric influenza vaccines |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| WO2022126416A1 (zh) * | 2020-12-16 | 2022-06-23 | 武汉友芝友生物制药股份有限公司 | 抗bcma抗体及其制备方法和应用 |
| CN112679614B (zh) * | 2021-01-15 | 2022-08-16 | 广东安普泽生物医药股份有限公司 | 用于特异性结合rankl靶向治疗药物的抗体及其用途 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN112946279A (zh) * | 2021-03-17 | 2021-06-11 | 扬州大学 | 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法 |
| MX2023011733A (es) | 2021-04-06 | 2023-10-13 | Abbvie Biotherapeutics Inc | Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin. |
| BR112023000666A2 (pt) | 2021-04-12 | 2023-10-24 | Academia Sinica | Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica |
| TWI895608B (zh) | 2021-04-29 | 2025-09-01 | 愛爾蘭商艾伯維製造管理無限公司 | 抗c-Met抗體藥物結合物 |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| JP2024541058A (ja) | 2021-11-03 | 2024-11-06 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 抗体の特異的共役 |
| EP4457243A4 (en) * | 2021-12-27 | 2025-12-17 | Academia Sinica | ANTIBODIES AGAINST THE SPIKE PROTEIN OF SARS-CoV-2 AND USES THEREOF |
| WO2024131846A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| US12318485B2 (en) | 2023-04-08 | 2025-06-03 | Rock Biomedical, Inc. | Methods and compositions for targeted delivery by polymersomes |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2840250C2 (de) | 1978-09-15 | 1983-01-20 | Siemens AG, 1000 Berlin und 8000 München | Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US7227002B1 (en) * | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1476120B1 (en) * | 2002-02-21 | 2010-09-29 | Duke University | Treatment methods using anti-cd22 antibodies |
| WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| JP5416338B2 (ja) * | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Ｃｄ２０特異的抗体およびその使用方法 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| WO2005058965A1 (en) * | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| PT1773885E (pt) * | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
| US20060094059A1 (en) | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
| AU2006213800B2 (en) * | 2005-02-10 | 2012-02-09 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| CA2854576A1 (en) | 2005-07-18 | 2007-01-25 | Haichun Huang | Human anti-b7rp1 neutralizing antibodies |
| US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
| BRPI0707480A8 (pt) | 2006-02-06 | 2022-11-08 | Vertical Bio Ag | Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos |
| JP5536445B2 (ja) | 2006-03-30 | 2014-07-02 | ノバルティス アーゲー | ｃ−Ｍｅｔの抗体の組成物およびその使用方法 |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
-
2007
- 2007-07-12 EP EP07301231A patent/EP2014681A1/en not_active Withdrawn
-
2008
- 2008-07-10 DK DK08786050.8T patent/DK2188312T3/en active
- 2008-07-10 PA PA20088789201A patent/PA8789201A1/es unknown
- 2008-07-10 HR HRP20150887TT patent/HRP20150887T1/hr unknown
- 2008-07-10 NZ NZ599959A patent/NZ599959A/xx unknown
- 2008-07-10 CA CA2981821A patent/CA2981821C/en active Active
- 2008-07-10 ES ES08786050.8T patent/ES2542059T3/es active Active
- 2008-07-10 ES ES12183761.1T patent/ES2686693T3/es active Active
- 2008-07-10 RU RU2010104633/10A patent/RU2552161C2/ru active
- 2008-07-10 AU AU2008274171A patent/AU2008274171B2/en active Active
- 2008-07-10 BR BRPI0815564A patent/BRPI0815564B8/pt active IP Right Grant
- 2008-07-10 ES ES11162718.8T patent/ES2686335T3/es active Active
- 2008-07-10 CL CL2008002015A patent/CL2008002015A1/es unknown
- 2008-07-10 ES ES11162720.4T patent/ES2678495T3/es active Active
- 2008-07-10 MX MX2014007693A patent/MX353449B/es unknown
- 2008-07-10 PT PT87860508T patent/PT2188312E/pt unknown
- 2008-07-10 EP EP08786050.8A patent/EP2188312B1/en active Active
- 2008-07-10 EP EP12183763.7A patent/EP2535357B1/en active Active
- 2008-07-10 KR KR1020167002899A patent/KR101701686B1/ko active Active
- 2008-07-10 WO PCT/EP2008/059026 patent/WO2009007427A2/en not_active Ceased
- 2008-07-10 NZ NZ599958A patent/NZ599958A/xx not_active IP Right Cessation
- 2008-07-10 SI SI200831467T patent/SI2188312T1/sl unknown
- 2008-07-10 CN CN200880024368.4A patent/CN101981054B/zh active Active
- 2008-07-10 KR KR1020107003216A patent/KR101625234B1/ko active Active
- 2008-07-10 HU HUE08786050A patent/HUE026026T2/en unknown
- 2008-07-10 CN CN201310478511.XA patent/CN103509112B/zh active Active
- 2008-07-10 EP EP11162718.8A patent/EP2415784B1/en active Active
- 2008-07-10 MY MYPI2010000127A patent/MY158756A/en unknown
- 2008-07-10 CA CA2888691A patent/CA2888691C/en active Active
- 2008-07-10 US US12/440,571 patent/US8329173B2/en active Active
- 2008-07-10 PL PL08786050T patent/PL2188312T3/pl unknown
- 2008-07-10 EP EP12183761.1A patent/EP2535356B1/en active Active
- 2008-07-10 JP JP2010515513A patent/JP5562844B2/ja active Active
- 2008-07-10 EP EP11162720.4A patent/EP2415785B1/en active Active
- 2008-07-10 KR KR1020167002898A patent/KR101701685B1/ko active Active
- 2008-07-10 SG SG2012050837A patent/SG183015A1/en unknown
- 2008-07-10 NZ NZ583041A patent/NZ583041A/en unknown
- 2008-07-10 MX MX2014008274A patent/MX345391B/es unknown
- 2008-07-10 CN CN201310478556.7A patent/CN103509113B/zh active Active
- 2008-07-10 KR KR1020157015922A patent/KR101719084B1/ko active Active
- 2008-07-10 NZ NZ613716A patent/NZ613716A/en not_active IP Right Cessation
- 2008-07-10 ES ES12183763.7T patent/ES2693542T3/es active Active
- 2008-07-10 CA CA2694418A patent/CA2694418C/en active Active
- 2008-07-10 CN CN201310073997.9A patent/CN103183739B/zh active Active
- 2008-07-10 ME MEP-2016-197A patent/ME02341B/me unknown
- 2008-07-10 CA CA2982484A patent/CA2982484C/en active Active
- 2008-07-10 RS RS20150560A patent/RS54197B1/sr unknown
- 2008-07-11 TW TW103121603A patent/TWI592427B/zh active
- 2008-07-11 TW TW097126356A patent/TWI549965B/zh active
- 2008-07-11 TW TW104114444A patent/TWI602829B/zh active
- 2008-07-11 AR ARP080102991A patent/AR067517A1/es active IP Right Grant
- 2008-07-11 TW TW104114445A patent/TWI602830B/zh active
- 2008-07-12 SA SA08290423A patent/SA08290423B1/ar unknown
-
2010
- 2010-01-03 IL IL203114A patent/IL203114A/en active IP Right Grant
- 2010-01-08 TN TNP2010000016A patent/TN2010000016A1/fr unknown
- 2010-01-08 MX MX2013010752A patent/MX341012B/es unknown
- 2010-02-10 MA MA32608A patent/MA31977B1/fr unknown
- 2010-02-10 ZA ZA2010/00966A patent/ZA201000966B/en unknown
- 2010-02-12 CO CO10016035A patent/CO6170364A2/es active IP Right Grant
-
2012
- 2012-11-09 US US13/673,716 patent/US8871910B2/en active Active
- 2012-11-09 US US13/673,752 patent/US9107907B2/en active Active
- 2012-11-09 US US13/673,726 patent/US8889832B2/en active Active
- 2012-11-09 US US13/673,690 patent/US8871909B2/en active Active
- 2012-11-18 IL IL223109A patent/IL223109B/en active IP Right Grant
- 2012-11-18 IL IL223106A patent/IL223106B/en active IP Right Grant
- 2012-11-18 IL IL223105A patent/IL223105B/en active IP Right Grant
- 2012-11-18 IL IL223108A patent/IL223108B/en active IP Right Grant
-
2014
- 2014-01-06 JP JP2014000618A patent/JP5889925B2/ja active Active
- 2014-01-06 JP JP2014000616A patent/JP5889923B2/ja active Active
- 2014-01-06 JP JP2014000617A patent/JP5889924B2/ja active Active
-
2015
- 2015-03-17 US US14/660,046 patent/US20150252114A1/en not_active Abandoned
- 2015-08-04 CY CY20151100680T patent/CY1116608T1/el unknown
-
2017
- 2017-09-15 AR ARP170102558A patent/AR109659A2/es unknown
- 2017-09-15 AR ARP170102559A patent/AR109660A2/es unknown
- 2017-09-15 AR ARP170102560A patent/AR109535A2/es unknown
-
2018
- 2018-09-24 PH PH12018502038A patent/PH12018502038A1/en unknown
- 2018-09-24 PH PH12018502039A patent/PH12018502039A1/en unknown
- 2018-09-24 PH PH12018502040A patent/PH12018502040A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815564B8 (pt) | anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met | |
| UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| FI3036258T3 (fi) | Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi | |
| BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| BR112022006001A2 (pt) | Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado | |
| BR112014007721A2 (pt) | processos para preparar compostos úteis como inibidores de atr quinase | |
| BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
| BRPI0923786C8 (pt) | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos | |
| BRPI0506726B8 (pt) | anticorpo monoclonal específico para m-csf e usos deste | |
| BR112018015238A2 (pt) | conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição | |
| BR112012016992A2 (pt) | "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena". | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| BR112014008775A2 (pt) | camundongo de cadeia pesada de imunoglobulina restrita | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BRPI0606891A2 (pt) | anticorpos dr5 e usos dos mesmos | |
| AR073459A1 (es) | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso | |
| EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
| BR112012030318A2 (pt) | composto específicos de anti-cd160 para o tratamento de transtornos oculares com base em neoangiogênese | |
| BR112012014984A2 (pt) | anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| BR112012018954A2 (pt) | derivados de hetaril-[1,8]naftiridina | |
| UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |